Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Rating of “Hold” by Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.92.

Several analysts have issued reports on CDLX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI began coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price for the company. Finally, Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th.

Insider Buying and Selling at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 25,118 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. The trade was a 17.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock valued at $237,767 in the last three months. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cardlytics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new position in Cardlytics during the third quarter worth about $82,000. Barclays PLC grew its stake in shares of Cardlytics by 223.9% in the third quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after purchasing an additional 40,112 shares during the last quarter. Geode Capital Management LLC increased its holdings in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Cardlytics in the 3rd quarter valued at about $63,000. Finally, RBF Capital LLC increased its stake in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after buying an additional 369,620 shares during the period. 68.10% of the stock is currently owned by institutional investors.

Cardlytics Stock Up 1.9 %

CDLX stock opened at $3.84 on Wednesday. The stock has a market capitalization of $195.16 million, a P/E ratio of -0.63 and a beta of 1.53. Cardlytics has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The business has a 50-day moving average of $3.91 and a 200-day moving average of $5.34. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. On average, sell-side analysts anticipate that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.